Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical stage biopharmaceutical company focused on discovering and developi ...
“We have done screens of over 2 million compounds and gotten anywhere from zero to tens of promising leads from screen hits, so if you screen any less chemical space, there is lower chance of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback